Pertuzumab Combo Improved Invasive DFS in HER2-Positive Breast Cancer

The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease –free survival in patients with HER2-positive early breast cancer.

Source: CancerNetwork - June 7, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer News Source Type: news